Aurore Life Sciences is an API manufacturer based in India. It holds 35 active US drug master files and 27 valid CEPs. Its filings concentrate with ARCSA (EC), PPB (KE) and UZPHARM (UZ). Its GMP standing is certified by EAEU_EEC, MFDS (Korea) and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 31 May 2024 as VAI. Customs aggregates show $10.3M of exports covering 143 molecules to 34 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Sangareddy, India | 3018005839 |
| Hyderabad, India | Not on file |
| Hyderabad, India | 3003937580 |
| Hyderabad, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Celecoxib | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Levetiracetam | EDQM, US FDA | 4 |
| Clozapine | EDQM, US FDA | 3 |
| Tolvaptan | SFDA (Saudi Arabia), US FDA | 3 |
| Valaciclovir | EDQM, US FDA | 3 |
| Aciclovir | EDQM | 2 |
| Acyclovir | US FDA | 2 |
| Amlodipine | EDQM, US FDA | 2 |
| Dronedarone | EDQM, US FDA | 2 |
| Favipiravir | US FDA | 2 |
| Levothyroxine | EDQM, US FDA | 2 |
| Losartan | EDQM, US FDA | 2 |
| Oxcarbazepine | EDQM, US FDA | 2 |
| Raloxifene | EDQM, US FDA | 2 |
| Tafamidis | US FDA | 2 |
| Valaciclovir Hydrochloride Hydrate | EDQM | 2 |
| Valganciclovir | EDQM, US FDA | 2 |
| Verapamil | EDQM, US FDA | 2 |
| Amlodipine Besilate | EDQM | 1 |
| Bilastine | US FDA | 1 |
| Dabigatran | US FDA | 1 |
| Dabigatran Etexilate Mesilate | EDQM | 1 |
| Desvenlafaxine | US FDA | 1 |
| Fesoterodine | US FDA | 1 |
| Flecainide | EDQM | 1 |
| Fluphenazine | US FDA | 1 |
| Indomethacin | US FDA | 1 |
| Levothyroxine Sodium | EDQM | 1 |
| Marbofloxacin | US FDA | 1 |
| Marbofloxacin For Veterinary Use | EDQM | 1 |
| Molnupiravir | US FDA | 1 |
| Nafamostat | US FDA | 1 |
| Prazosin | US FDA | 1 |
| Raltegravir Potassium | EDQM | 1 |
| Risperidone | EDQM | 1 |
| Salsalate | US FDA | 1 |
| Sodium Cromoglicate | EDQM | 1 |
| Sulindac | US FDA | 1 |
| Tofacitinib | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 36 | None |
| PPB (KE) | 26 | None |
| UZPHARM (UZ) | 25 | None |
| MINSA (CR) | 18 | None |
| INVIMA (CO) | 14 | None |
| RCETH (BY) | 10 | None |
| EAEU_EEC | None | 7 |
| MFDS (Korea) | None | 2 |
| EMA | None | 1 |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $6.2M | 25 |
| 2025 | Not reported | $10.3M | 34 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Aurore Life Sciences comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.